Your browser doesn't support javascript.
loading
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni, Luca; Pienkowski, Tadeusz; Im, Young-Hyuck; Tseng, Ling-Ming; Liu, Mei-Ching; Lluch, Ana; Staroslawska, Elzbieta; de la Haba-Rodriguez, Juan; Im, Seock-Ah; Pedrini, Jose Luiz; Poirier, Brigitte; Morandi, Paolo; Semiglazov, Vladimir; Srimuninnimit, Vichien; Bianchi, Giulia Valeria; Magazzù, Domenico; McNally, Virginia; Douthwaite, Hannah; Ross, Graham; Valagussa, Pinuccia.
Afiliação
  • Gianni L; Oncologia Medica, San Raffaele Cancer Centre, Milan, Italy. Electronic address: gianni.luca@hsr.it.
  • Pienkowski T; Postgraduate Medical Education Centre, Warsaw, Poland.
  • Im YH; Samsung Medical Centre, Seoul, South Korea.
  • Tseng LM; Taipei-Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan.
  • Liu MC; Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan.
  • Lluch A; Hospital Clínico Universitario, INCLIVA Health Research Institute, University of Valencia, Valencia, Spain.
  • Staroslawska E; St John's Cancer Centre, Lublin, Poland.
  • de la Haba-Rodriguez J; Oncology Department, Maimonides Institute of Biomedical Research, Reina Sofía Hospital, University of Córdoba, Córdoba, Spain.
  • Im SA; Division of Hematology/Medical Oncology, Department of Internal Medicine, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Pedrini JL; Hospital Nossa Senhora da Conceição, Hospital Ernesto Dornelles, Porto Alegre, Brazil.
  • Poirier B; Hôpital du Saint-Sacrément, Centre Hospitalier Affilié Universitaire de Québec, Québec, Canada.
  • Morandi P; Medical Oncology Department, Ospedale dell'Angelo Mestre, Ospedale San Giovanni e Paolo Venezia, Venice, Italy.
  • Semiglazov V; N N Petrov Research Institute of Oncology, St Petersburg, Russia.
  • Srimuninnimit V; Medical Oncology Unit, Department of Medicine, Siriraj Hospital, Bangkok, Thailand.
  • Bianchi GV; Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy.
  • Magazzù D; Fondazione Michelangelo, Milan, Italy.
  • McNally V; Roche Products Limited, Welwyn, UK.
  • Douthwaite H; Roche Products Limited, Welwyn, UK.
  • Ross G; Roche Products Limited, Welwyn, UK; AstraZeneca, Melbourn, Cambridge, UK.
  • Valagussa P; Fondazione Michelangelo, Milan, Italy.
Lancet Oncol ; 17(6): 791-800, 2016 Jun.
Article em En | MEDLINE | ID: mdl-27179402
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadjuvante / Neoplasias Inflamatórias Mamárias / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 / Terapia Neoadjuvante / Neoplasias Inflamatórias Mamárias / Recidiva Local de Neoplasia Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2016 Tipo de documento: Article